Effects of Epirubicin/Docetaxel on Plasma Proteins in Breast Cancer
Author Information
Author(s): Michlmayr A, Bachleitner-Hofmann T, Bergmann M, Oehler R
Primary Institution: Medical University of Vienna
Hypothesis
Does the protein expression profile in plasma samples from breast cancer patients change in response to the initial dose of epirubicin/docetaxel therapy?
Conclusion
The study found that the initial dose of epirubicin/docetaxel therapy modulates the expression of several plasma proteins, including IαI and complement components.
Supporting Evidence
- The abundance of several IαI spots increased in nearly all patients after treatment.
- Total plasma C3 levels decreased in response to the therapy.
- There was a negative correlation between IαI levels and total plasma C3.
Takeaway
When breast cancer patients receive their first dose of a specific treatment, some proteins in their blood change, which might help doctors understand how the treatment is working.
Methodology
The study used two-dimensional gel electrophoresis to analyze plasma proteins and measured total plasma C3 levels by immunonephelometry.
Limitations
The study did not identify the reactions of all IαI isoforms to therapy and did not correlate all IαI spots with therapy success.
Participant Demographics
Breast cancer patients receiving epirubicin/docetaxel therapy.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website